Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease

被引：0
|
作者：
Kyohei Isshiki
Takahiro Kamiya
Akifumi Endo
Kentaro Okamoto
Tomoo Osumi
Toshinao Kawai
Katsuhiro Arai
Daisuke Tomizawa
Kazuo Ohtsuka
Masakazu Nagahori
Kohsuke Imai
Motohiro Kato
Hirokazu Kanegane
机构：
[1] National Center for Child Health and Development,Children’s Cancer Center
[2] Tokyo Medical and Dental University Hospital,Department of Pediatrics
[3] Tokyo Medical and Dental University Hospital,Department of Pediatric Surgery
[4] National Center for Child Health and Development,Division of Immunology
[5] National Center for Child Health and Development,Division of Gastroenterology
[6] Tokyo Medical and Dental University Hospital,Department of Gastroenterology and Hepatology
来源：
International Journal of Hematology | 2022年 / 115卷
关键词：
Vedolizumab; GVHD; Children; Gastrointestinal tract; Refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vedolizumab, an immunosuppressive drug that acts locally on the gastrointestinal tract, is mainly used for the treatment of inflammatory bowel disease, and has been reported to be effective against gastrointestinal acute graft-versus-host disease (GI-aGVHD) in adults. However, there is insufficient evidence for pediatric GI-aGVHD. We used vedolizumab to treat three cases of GI-aGVHD in patients aged 1.5–4.4 years. It was significantly effective in two patients and did not cause serious side effects in any patient. Vedolizumab might be effective and safe for pediatric GI-aGVHD refractory to other treatments, but this must be confirmed in future studies.
引用
收藏
页码：590 / 594
页数：4
相关论文
共 50 条
  • [31] Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease
    Yalniz, Fevzi E.
    Hefazi, Mehrdad
    McCullough, Kristen
    Litzow, Mark R.
    Hogan, William J.
    Wolf, Robert
    Alkhateeb, Hassan
    Kansagra, Ankit
    Damlaj, Moussab
    Patnaik, Mrinal M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) : 1478 - 1484
  • [32] Ruxolitinib for Steroid-Refractory Acute Graft-Versus-Host Diseas
    Toama, Wael
    Fiala, Mark A.
    Pusic, Iskra
    Westervelt, Peter
    DiPersio, John F.
    Schroeder, Mark A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [33] Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease
    Freyer, Craig W.
    Gier, Shannon
    Carulli, Alison
    Gill, Saar I.
    Hexner, Elizabeth O.
    Loren, Alison W.
    Martin, Mary Ellen
    Porter, David L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (07) : E273 - E276
  • [34] Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease
    Jerkins, James H.
    Hamadani, Mehdi
    Zook, Felicia
    Epperla, Narendranath
    Shaw, Bronwen E.
    Saber, Wael
    Rizzo, J. Douglas
    Pasquini, Marcelo
    Chhabra, Saurabh
    Drobyski, William R.
    Hari, Parameswaran N.
    Shah, Nirav N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : E610 - E611
  • [35] Strategy on the Treatment of Steroid-Refractory Severe acute Graft-versus-Host Disease
    Yamin, T.
    Yi, L.
    Kaili, D.
    He, H.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S393 - S394
  • [36] Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract
    Alex Ganetsky
    Noelle V. Frey
    Elizabeth O. Hexner
    Alison W. Loren
    Saar I. Gill
    Selina M. Luger
    James K. Mangan
    Mary Ellen Martin
    Daria V. Babushok
    William R. Drobyski
    Jacqueline Smith
    Colleen Timlin
    Craig W. Freyer
    Edward A. Stadtmauer
    David L. Porter
    Bone Marrow Transplantation, 2019, 54 : 212 - 217
  • [37] Treatment of steroid-refractory acute graft-versus-host disease with ATG (Fresenius)
    Kamelander, J.
    Navratil, M.
    Koristek, Z.
    Doubek, M.
    Krejci, M.
    Brychtova, Y.
    Racil, Z.
    Mendelova, D.
    Weinreb, M.
    Mayer, J.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S241 - S241
  • [38] Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
    Benito, AI
    Furlong, T
    Martin, PJ
    Anasetti, C
    Appelbaum, FR
    Doney, K
    Nash, RA
    Papayannopoulou, T
    Storb, R
    Sullivan, KM
    Witherspoon, R
    Deeg, HJ
    TRANSPLANTATION, 2001, 72 (12) : 1924 - 1929
  • [39] Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract
    Ganetsky, Alex
    Frey, Noelle V.
    Loren, Alison W.
    Hexner, Elizabeth O.
    Mangan, James K.
    Gill, Saar I.
    Luger, Selina
    Cohen, Adam D.
    Babushok, Daria V.
    Stadtmauer, Edward A.
    Smith, Jacqueline
    Drobyski, William R.
    Kraus, Sarah K.
    Timlin, Colleen
    Porter, David L.
    BLOOD, 2016, 128 (22)
  • [40] Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract
    Ganetsky, Alex
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Loren, Alison W.
    Gill, Saar I.
    Luger, Selina M.
    Mangan, James K.
    Martin, Mary Ellen
    Babushok, Daria V.
    Drobyski, William R.
    Smith, Jacqueline
    Timlin, Colleen
    Freyer, Craig W.
    Stadtmauer, Edward A.
    Porter, David L.
    BONE MARROW TRANSPLANTATION, 2019, 54 (02) : 212 - 217
12345